Cancer / Immunology
Nutshell Therapeutics Secures FDA IND Clearance for AI-Discovered NRF2 Degrader NTS231
Nutshell Therapeutics (Shanghai) Co., Ltd. ("Nutshell Therapeutics"), an innovative biotech company focused on AI-driven allosteric drug discovery, announc...
September 28, 2026 | News
Astellas Doses First Patient in Phase 3 Trial of Setidegrasib for KRAS G12D-Mutated Lung Cancer
Study evaluates novel, investigational KRAS G12D-targeted protein degrader setidegrasib versus docetaxel in previously treated patients with advanc...
September 25, 2026 | News
Massive Bio Targets South Korea Expansion for AI-Powered Oncology Trial Matching
US healthtech company Massive Bio has appointed international business development consultancy Intralink to support its expansion into South Korea and buil...
September 21, 2026 | News
Ferronova’s Nanoparticle Platform Shows Promise for More Precise Gastric and Oesophageal Cancer Surgery
Australian medical technology company Ferronova has announced preliminary findings from the MAGMAP multi-centre trial involving 62 gastric and oesopha...
September 17, 2026 | News
AstraZeneca, Daiichi Sankyo’s ENHERTU Cuts Disease Progression Risk by 37% in HER2-Mutant Lung Cancer
AstraZeneca and Daiichi Sankyo’s ENHERTU is the first HER2-directed therapy to delay disease progression over standard of care in a Phase III trial...
September 16, 2026 | News
Kelun-Biotech’s Trastuzumab Botidotin Cuts Progression Risk by 61% in Phase III Breast Cancer Study
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or "the Company", 6990.HK) announced that results from the phase III registrational...
September 15, 2026 | News
Solstice Oncology Launches with $225M Series A to Advance Harbour BioMed’s Porustobart
Porustobart, a second-generation Fc-enhanced CTLA-4 antibody, is being advanced across two clinical indications in the neoadjuvant setting, beginning...
September 11, 2026 | News
Kazia Doses First Patient in Phase II Study of Paxalisib Combination for Aggressive Paediatric Brain Cancer
Multicenter study to evaluate paxalisib plus gemcitabine for children and young adults with recurrent or progressive AT/RT, where no approved therapies cur...
September 11, 2026 | News
EpiVax Adds AI-Enabled Enhancements to ISPRI Immunogenicity Risk Platform
EpiVax, Inc. is pleased to announce the release of AI-enabled enhancements to ISPRI™, its proprietary in silico platform for assessing the ...
September 04, 2026 | News
Cartherics Explores Tissue Factor-Targeting CAR-NK Therapies for Cancer and Endometriosis
Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immu...
September 03, 2026 | News
US FDA Grants Fast Track Designation to T-MAXIMUM’s Allogeneic CAR-T Therapy for Recurrent Glioblastoma
T-MAXIMUM PHARMACEUTICAL Inc. ("T-MAXIMUM") announced that its investigational allogeneic CAR-T cell therapy MT027 has been granted Fast Track Designation ...
September 02, 2026 | News
DarwinHealth Unveils AI-Powered ‘Quantum Cancer Biology’ Framework to Decode Drug-Resistant Tumours
New paradigm integrates single-cell transcriptomics, regulatory network inference, and AI to decode—and therapeutically target—the multiple, co...
August 28, 2026 | News
US FDA Approves BeOne’s TEVIMBRA-ZIIHERA Combination for First-Line HER2+ Gastroesophageal Cancer
TEVIMBRA plus ZIIHERA and chemotherapy is the first and only immunotherapy-based regimen to deliver more than two years of median OS in first-line HER2+ ...
August 27, 2026 | News
Taiwan’s Anbogen Partners University of Tokyo to Advance ABT-301 Across Solid Tumours
Anbogen Therapeutics Inc. (TPEx: 7784) ("Anbogen" or the "Company"), a clinical-stage precision oncology company, announced that it has entered into a Coll...
August 25, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
